Suppr超能文献

ABCC8 显性突变致药物难治性高胰岛素血症低血糖症。

Dominantly acting ABCC8 mutations in patients with medically unresponsive hyperinsulinaemic hypoglycaemia.

机构信息

Institute of Biomedical and Clinical Science, Peninsula Medical School, University of Exeter, Exeter, UK.

出版信息

Clin Genet. 2011 Jun;79(6):582-7. doi: 10.1111/j.1399-0004.2010.01476.x.

Abstract

Recessive inactivating mutations in the ABCC8 and KCNJ11 genes encoding the adenosine triphosphate-sensitive potassium (K(ATP)) channel subunit sulphonylurea receptor 1 (SUR1) and inwardly rectifying potassium channel subunit (Kir6.2) are the most common cause of hyperinsulinaemic hypoglycaemia (HH). Most of these patients do not respond to treatment with the (K(ATP)) channel agonist diazoxide. Dominant inactivating ABCC8 and KCNJ11 mutations are less frequent, but are usually associated with a milder form of hypoglycaemia that is responsive to diazoxide therapy. We studied five patients from four families with HH who were unresponsive to diazoxide and required a near total pancreatectomy. Mutations in KCNJ11 and ABCC8 were sought by sequencing and dosage analysis. Three novel heterozygous ABCC8 mis-sense mutations (G1485E, D1506E and M1514K) were identified in four probands. All the mutations affect residues located within the Nucleotide Binding Domain 2 of the SUR1 subunit. Testing of family members showed that the mutations had arisen de novo with dominant inheritance in one pedigree. This study extends the clinical phenotype associated with dominant (K(ATP)) channel mutations to include severe congenital HH requiring near total pancreatectomy in addition to a milder form of diazoxide responsive hypoglycaemia. The identification of dominant vs recessive mutations does not predict clinical course but it is important for estimating the risk of HH in future siblings and offspring.

摘要

ABCC8 和 KCNJ11 基因的隐性失活突变,这些基因编码三磷酸腺苷敏感钾 (K(ATP)) 通道亚单位磺酰脲受体 1 (SUR1) 和内向整流钾通道亚单位 (Kir6.2),是导致高胰岛素血症性低血糖症 (HH) 的最常见原因。这些患者大多数对 K(ATP) 通道激动剂二氮嗪的治疗没有反应。显性失活的 ABCC8 和 KCNJ11 突变较少见,但通常与低血糖症较轻有关,对二氮嗪治疗有反应。我们研究了来自四个家庭的五名对二氮嗪无反应且需要进行近全胰切除术的 HH 患者。通过测序和剂量分析寻找 KCNJ11 和 ABCC8 的突变。在四个先证者中发现了三个新的杂合 ABCC8 错义突变 (G1485E、D1506E 和 M1514K)。所有突变均影响位于 SUR1 亚单位核苷酸结合域 2 内的残基。对家庭成员的测试表明,这些突变是在一个家系中新生的,具有显性遗传。这项研究将与显性 (K(ATP)) 通道突变相关的临床表型扩展到包括严重的先天性 HH,除了轻度的二氮嗪反应性低血糖症外,还需要进行近全胰切除术。显性与隐性突变的鉴定不能预测临床病程,但对于估计未来兄弟姐妹和后代的 HH 风险很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9608/3375476/fd01982e4d22/cge0079-0582-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验